| HOME >> BIOLOGY >> TECHNOLOGY |
Astex Therapeutics Develops Structure of Cyclin Dependent Kinase 4 II-49
Astex Teams up with Cancer Research UK on Clinical Trials of AT9283 II-49
Astex Presents AT7519, a Cyclin Dependent Kinase Inhibitor II-49
Cell Biosciences Unveils First Kits for Oncoprotein Analysis II-50
Plexxikon Partners with Roche to Develop and Commercialize PLX5568 II-50
OSI Applies Additional NDA for Tarceva II-50
KAI and BMS Forms Global Alliance on KAI-9803 II-51
Kosan Biosciences Commences Phase II Trial for Alvespimycin II-51
Plexxikon Announces Commencement of Phase 1 PLX5568 Trial II-51
Exelixis Instigates Phase III XL184Trial II-51
Oncothyreon Commences Phase I PX-866 Clinical Trial II-52
Iressa As Efficient as Chemotherapy for Lung Cancer II-52
Iressa Proves Useful for Non-smoker Patients II-52
GPC Biotech Commence Enrollment in Phase 1 RGB-286638 Trial II-52
AVEO Commences Phase I Clinical Trials of AV-951 II-52
Onyx and Bayer Secure FDA and EC Approval for Nexavar(R) II-53
Product Patent Application for Iressa Rejected II-53
OSI Pharmaceuticals to Launch Tarceva(R) in Japan II-53
New Plk1 Kinase Inhibitor BI 2536 Developed II-54
Kinex Files IND Application for KX2-391 II-54
Wyeth Receives FDA Approval for TORISEL for Advanced Renal Cancer Treatment II-54
Nexavar Gets Approval from Swiss Authorities for Treatment of Kidney Cancer (Switzerland) II-54
5. RECENT INDUSTRY ACTIVITY II-55
Merck Agrees to Merge with Schering-Plough II-55
Pfizer Agrees to Acquire Wyeth II-55
S*BIO, Tragara Signs Exclusive Agreement II-55
GPC Biotech to Merge with Agennix II-55
Sanofi-Aventis to acquire Bipar Sciences II-56
Pfizer Takes Over Serenex II-56
Roche to Acquire Piramed II-56
Eli Lilly Acquires SGX Pharmaceuticals II-57
Takeda Acquires
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |